SOHO 2020 | Long-term outcomes of anti-CD19 CAR-T in R/R CLL

David L. Porter, MD, University of Pennsylvania, Abramson Cancer Center, Philadelphia, PA, explores the long-term outcomes from a randomized dose optimization study of CAR-modified T-cells in relapsed/refractory (R/R) chronic lymphoyctic leukemia (CLL). This interview was recorded via an online conference call with The Video Journal of Regenerative Medicine (VJRegenMed).